banner

Posts tagged as: new cancer drugs back to homepage

Cellceutix Clinical Trials at Dana Farber and Beth Israel Deaconess Now Active Cellceutix Clinical Trials at Dana Farber and Beth Israel Deaconess Now Active(0)

The day of dosing cancer patients with Kevetrin is drawing near according to news this morning from Cellceutix Corporation (OTCBB: CTIX). The Beverly, Massachusetts-based company said today that clinical trials for their novel anti-cancer drug have gone active at Harvard’s Dana-Farber Cancer Center and partner Beth Israel Deaconess Medical Center. Dosing should begin within Read More

Breast Cancer News:  Geron Drug Fails, Herceptin May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials Breast Cancer News: Geron Drug Fails, Herceptin May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials(0)

Nobody said developing a new cancer drug was easy.  Geron Corp. (NASDAQ: GERN) shares took a nosedive last Monday, falling more than 50 percent as the drug maker disclosed that it is discontinuing a randomized Phase II clinical trial of its anti-cancer drug Imetelstat in metastatic HER2-negative breast cancer patients.  Menlo Park, California-based Geron said that the median progression-free survival in the Imetelstat arm was shorter than in the comparator arm in the trial.  Imetelstat was being evaluated in combination with paclitaxel, compared to Read More

Cellceutix Cancer Drug Expanding to Three Different Clinical Trials Cellceutix Cancer Drug Expanding to Three Different Clinical Trials(0)

There is starting to be a steady buzz across the web about Cellceutix Corporation (OTCBB: CTIX) and its novel cancer drug, Kevetrin™.  For starters, the p53-activating drug is on tap to begin dosing patients with solid tumors any day now in clinical trials at the vaunted Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.  Second, Cellceutix has reported that Beth Israel Read More

Cellceutix on Seeking Alpha:  Pfizer Eyes Kevetrin? Cellceutix on Seeking Alpha: Pfizer Eyes Kevetrin?(0)

An article from August 13 by Seeking Alpha contributor A. Jackson discussed the state of big pharma’s pipelines and the potential of Cellceutix (OTCBB: CTIX) anti-cancer drug, Kevetrin, as it enters clinical trials at Dana-Farber and Beth Israel Deaconess. More acutely, Jackson details the relationship between Pfizer and Cellceutix and why the smaller biotech could be a logical acquisition target for the world’s biggest drug maker. Read More

IsoRay and Others Shifting the Paradigm of Traditional Standards of Care in Cancer IsoRay and Others Shifting the Paradigm of Traditional Standards of Care in Cancer(0)

The fight against cancer is an ongoing evolution with new technologies, procedures and compounds showing potent anti-tumor activities as stand-alone treatments or working in conjunction with traditional therapies to increase survival rates. Pioneering efforts of companies like Immunocellar Therapeutics Ltd. (NYSE MKT: IMUC), Cellceutix Corporation (OTCBB: CTIX) and IsoRay Inc. (NYSE MKT: ISR) are advancing cancer research and providing additional hope for cancer sufferers. Read More

Cellceutix CEO and Advisor Jim Boeheim Interviewed by Boston Herald About New Cancer Drug Cellceutix CEO and Advisor Jim Boeheim Interviewed by Boston Herald About New Cancer Drug(0)

Company Provides Update on p53 Compounds From Annual ASCO Meeting

Cellceutix Corporation (CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers, is pleased to report that its Chief Executive Officer, Leo Ehrlich, and Cellceutix advisor Jim Boeheim, Read More

FDA to Expedite the Drug Approval Process for Breakthroughs FDA to Expedite the Drug Approval Process for Breakthroughs(0)

An article released yesterday by Reuters titled, “U.S. may speed approval of ‘breakthrough’ drugs” could prove extremely valuable for biotechs of all sizes.  According to the article,

Experimental drugs that show a big effect early in development for treating serious or life-threatening diseases would get a faster and cheaper path to U.S. approval, under a proposal likely to become law this year. Read More

Jim Boeheim and Cellceutix Team to Fight Cancer Jim Boeheim and Cellceutix Team to Fight Cancer(0)

Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers),is pleased to announce that Syracuse University’s legendary men’s basketball coach Jim Boeheim has joined Cellceutix as an advisor to the Company. Read More

Cellceutix Novel Anti-Cancer Compound Kevetrin Presented at AACR Annual Meeting Cellceutix Novel Anti-Cancer Compound Kevetrin Presented at AACR Annual Meeting(0)

Company on Schedule for Filing Amended IND -

Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing small molecule drugs to treat severe medical conditions, including drug-resistant cancers, is pleased to provide shareholders an update on developments with its novel anti-cancer compound Kevetrin™. Read More

Sunshine Biopharma Shares Jump on Multi-Drug Resistant Breast Cancer Presentation News Sunshine Biopharma Shares Jump on Multi-Drug Resistant Breast Cancer Presentation News(0)

With the backdrop of news on Monday that Sunshine Biopharma, Inc. (OTCBB:SBFM) will be presenting new scientific data at the American Association for Cancer Research Meeting in Chicago, IL (to be held on March 31 – April 4, 2012), shares of the junior biotech surged a cool 100% to close Monday’s trading at 50 cents each. Read More



Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.